RecruitingNCT06357741

Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Enrollment

30 participants

Start Date

Aug 1, 2021

Study Type

OBSERVATIONAL

Conditions

Knee Osteoarthritis

Summary

As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.

Eligibility

Min Age: 45 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Denosumab for people with knee osteoarthritis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 45 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.